This site is intended for Healthcare professionals only.

Potential Zika virus vaccine shows promise


Potential Zika virus vaccine shows promise

Preclinical results of research by City College of New York scientists and TechnoVax, Inc. in animal models demonstrate favorable outcomes in developing a vaccine against the mosquito-borne Zika virus. The results were announced by Tarrytown, New York-based TechnoVax, a biotechnology developer of novel vaccines whose proprietary virus-like particle (VLP) is the center of the research.

CUNY School of Medicine at City College faculty, Paul Gottlieb and Linda Spatz, and Al Katz of the CCNY Physics Department, are collaborating with TechnoVax.

The VLP vaccine formulations tested in animals not only were highly effective in eliciting protective antibodies with neutralizing activity equivalent to or higher than the activity present in the serum of a patient who recovered from Zika infection but also were well tolerated and safe. “The ZIKA VLP vaccine offers an effective and safe strategy to create a prophylactic vaccine that protect against Zika infection as well as its serious effects such as microcephaly,” said Jose M. Galarza, TechnoVax CEO.

The ultimate goal of the collaboration is to expand the translational research with TechnoVax by completing the Zika vaccine development and initiate new vaccine projects directed to additional virus pathogens.

The study has been accepted for publication in the journal PLOS Neglected Tropical Diseases.

According to the Atlanta-based Centers for Disease Control and Prevention, Zika is spread mostly by the bite of an infected Aedes species mosquito. It can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause certain birth defects. There is no vaccine or medicine for Zika. Local mosquito-borne Zika virus transmission has been reported in the continental United States.

Full Article by :  Hélène Boigard, Alexandra Alimova, George R. Martin, Al Katz, Paul Gottlieb, Jose M. Galarza. Zika virus-like particle (VLP) based vaccine. PLOS Neglected Tropical Diseases, 2017; 11 (5): e0005608 DOI: 10.1371/journal.pntd.0005608

The following two tabs change content below.
supriya kashyap

supriya kashyap

Supriya Kashyap Joined Medical Dialogue as Reporter in 2015 . she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Delhi University. She can be contacted at supriya.kashyap@medicaldialogues.in Contact no. 011-43720751
Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted